Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hI-con1 in Neovascular AMD
NCT01485588Phase 2Completed
- Sponsor
- Iconic Therapeutics, Inc.
- Start
- Dec 2010
- Primary completion
- Mar 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of hI-con1 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Iconic Therapeutics, Inc. Primary endpoints: Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at 24 weeks, Mean Change in Best Corrected Visual Acuity (BCVA) at 24 weeks and 1 more. Started Dec 2010; status: completed.
02
Drugs
hI-con1
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01485588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485588.